Literature DB >> 30451300

The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

Peer Tfelt-Hansen1, Elizabeth Loder2.   

Abstract

Entities:  

Keywords:  CGRP antagonists; miregepant; ubrogepant

Mesh：

Substances：

Year:  2018        PMID： 30451300     DOI： 10.1111/head.13444

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


× No keyword cloud information.
  10 in total

1.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

2.  Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine.

Authors:  Lite Yang; Mengyi Xu; Shamsuddin A Bhuiyan; Jia Li; Jun Zhao; Randall J Cohrs; Justin T Susterich; Sylvia Signorelli; Ursula Green; James R Stone; Dan Levy; Jochen K Lennerz; William Renthal
Journal:  Neuron       Date:  2022-03-28       Impact factor: 18.688

3.  Rimegepant for the treatment of migraine.

Authors:  Amnon A Berger; Ariel Winnick; Austin H Carroll; Alexandra Welschmeyer; Nathan Li; Marc Colon; Antonella Paladini; Giovanni F Ramírez; Jamal Hasoon; Elyse M Cornett; Jaehong Song; Giustino Varrassi; Adam M Kaye; Alan D Kaye; Latha Ganti
Journal:  Health Psychol Res       Date:  2022-10-12

Review 4.  Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.

Authors:  Peer Tfelt-Hansen; Karl Messlinger
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

Review 5.  Therapeutic novelties in migraine: new drugs, new hope?

Authors:  Thien Phu Do; Song Guo; Messoud Ashina
Journal:  J Headache Pain       Date:  2019-04-17       Impact factor: 7.277

Review 6.  The Role of Anti-calcitonin Gene-related Peptide in Migraine and its Implication in Developing Countries: A Reasonable Option to Consider Despite Higher Cost.

Authors:  Ali Akhtar
Journal:  Cureus       Date:  2019-06-01

Review 7.  The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

Authors:  Willem Sebastiaan van Hoogstraten; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2019-05-16       Impact factor: 7.277

8.  Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials.

Authors:  Bixi Gao; Yanbo Yang; Zilan Wang; Yue Sun; Zhouqing Chen; Yun Zhu; Zhong Wang
Journal:  Front Pharmacol       Date:  2020-01-24       Impact factor: 5.810

9.  A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.

Authors:  Caroline M Kopruszinski; Edita Navratilova; Juliana Swiokla; David W Dodick; Iain P Chessell; Frank Porreca
Journal:  Cephalalgia       Date:  2020-09-26       Impact factor: 6.292

10.  The Value of Headache-Specific Recommendations During COVID-19.

Authors:  Rebecca Erwin Wells; Lauren Doyle Strauss
Journal:  Headache       Date:  2020-05       Impact factor: 5.887
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.